SELLAS Life Sciences reports 'promising' cancer vaccine PhII data; Aridis Pharmaceuticals gets NIH grant to develop vaccine storage tech;

> SELLAS Life Sciences announced that in a Phase II study of its WT1 cancer vaccine in malignant pleural mesothelioma patients, top-line data demonstrated clinical significant increases in overall survival and progression-free survival. Release

> Aridis Pharmaceuticals announced that it has received several National Institutes of Health grants, one of which is to develop technology to encase proteins into room temperature stable formulations for simpler vaccines storage. Release

> An attempt to repeal California's strict vaccination requirements for schoolchildren fell short of signatures. More

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.